Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a for-profit pharmaceutical manufacturer headquartered in Parsippany, New Jersey, that specializes in the production and distribution of specialty biopharmaceutical products. The company has established itself as a key supplier to the federal government through its registration with SAM.gov since January 2007, maintaining an active registration through July 2026. Ferring's primary role in the federal contracting landscape is as a manufacturer and supplier of pharmaceutical goods, particularly specialized oncology medications, through vehicles established with the U.S. Department of Veterans Affairs.

Ferring Pharmaceuticals Inc. has consistently supplied the Department of Veterans Affairs with Adstiladrin (nadofaragene firadenovec), a specialized treatment for genitourinary and bladder cancers used to support veteran healthcare services. The company has received numerous delivery orders under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) from various Veterans Integrated Service Networks (VISNs) across the United States, including VISN 2, VISN 5, VISN 8, VISN 9, VISN 10, VISN 16, VISN 20, and VISN 22. These delivery orders have ranged in value from approximately $45,829 to $274,975, with the largest order totaling $274,974.90 issued as an emergency procurement for the Lake Nona VA Medical Center. All delivery orders have been issued on a firm-fixed price basis with no set-aside designations, indicating open competitive procurement. The company fulfills orders from its facilities in both Parsippany, New Jersey, and Carrollton, Texas, demonstrating its operational capacity to support geographically dispersed VA medical centers and clinics nationwide. As of the most recent awards, Ferring has maintained an active supply relationship with the VA through 2025 and into 2026, confirming its continued status as a critical pharmaceutical supplier to the federal government.

Ferring Pharmaceuticals Inc. holds two primary indefinite-delivery vehicles with the Department of Veterans Affairs under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The first is a multiple-award indefinite-delivery contract valued at $98.2 million with a period of performance from June 1, 2020, through December 31, 2025, which has served as the parent vehicle for the majority of Adstiladrin delivery orders issued to various VISNs. The second is a single-award Blanket Purchase Agreement valued at $5.96 million awarded on March 15, 2024, and extending through March 14, 2026, which provides an additional procurement mechanism for Adstiladrin supply. Both IDVs are specifically structured to enable streamlined procurement of Adstiladrin across VA medical centers and clinics nationwide, supporting the VA's mission to provide comprehensive oncology treatment options to veterans. The multiple-award contract structure allows for concurrent ordering arrangements, while the single-award BPA offers a dedicated procurement pathway. These vehicles have generated substantial transactional activity, with numerous delivery orders ranging from $45,000 to $275,000 issued across multiple fiscal years, demonstrating the VA's continued reliance on Ferring as a specialized oncology pharmaceutical supplier.